echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Domestic 100 years only approved one, most of the vaccine companies do not have the production capacity, where is the "neck" of domestic vaccine adjuvants? Who will break the import monopoly?

    Domestic 100 years only approved one, most of the vaccine companies do not have the production capacity, where is the "neck" of domestic vaccine adjuvants? Who will break the import monopoly?

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    At the moment when the financing "cold winter" and the new crown vaccine market have "gone", the research and development of new adjuvant vaccines is increasingly optimistic
    .


    01 Where is the "neck" of domestic adjuvants stuck?

    Where is the "neck" of domestic adjuvants stuck? neck

    According to the "2022-2026 China Vaccine Adjuvant Industry Market Monitoring and Future Development Prospect Research Report" released by the New Sijie Industry Research Center, in 2021, the global vaccine adjuvants market sales exceeded 840 million US dollars, and globally, North America is the largest vaccine adjuvants market, accounting for nearly 40% of the market, followed by Europe
    .


    02 80% of domestic vaccines use aluminum adjuvants

    80% of domestic vaccines use aluminum adjuvants

    At present, China's listed vaccines are still dominated by aluminum adjuvants, and the earliest aluminum salt adjuvants were approved for listing in 1926, and for many years, insoluble aluminum salts have been the only adjuvants
    in licensed products.


    03 The import monopoly of new adjuvants may be broken

    The import monopoly of new adjuvants may be broken

    "The same antigen, if there is a new adjuvant, the yield is increased by dozens of times, and the protection rate can also be improved
    .


    Resources:

    Resources:

    [1] ZHOU Yang,GENG Xingchao,WANG Jufeng,LI Bo.


    [1] ZHOU Yang,GENG Xingchao,WANG Jufeng,LI Bo.


    [2] E Drug Manager "Ruike Biologics: A Model for Innovation of Chinese Vaccine Enterprises"
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.